National Bank of Canada FI Buys Shares of 105,700 10x Genomics, Inc. (NASDAQ:TXG)

National Bank of Canada FI bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 105,700 shares of the company's stock, valued at approximately $1,518,000. National Bank of Canada FI owned approximately 0.09% of 10x Genomics at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in TXG. JPMorgan Chase & Co. raised its position in shares of 10x Genomics by 355.0% in the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after purchasing an additional 277,355 shares during the period. Entropy Technologies LP boosted its holdings in shares of 10x Genomics by 285.6% during the fourth quarter. Entropy Technologies LP now owns 37,595 shares of the company's stock worth $540,000 after acquiring an additional 27,844 shares during the period. Geode Capital Management LLC increased its stake in shares of 10x Genomics by 2.4% during the third quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company's stock worth $41,009,000 after purchasing an additional 42,777 shares during the period. SG Americas Securities LLC lifted its holdings in 10x Genomics by 209.8% during the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company's stock worth $1,049,000 after purchasing an additional 49,468 shares during the last quarter. Finally, Alberta Investment Management Corp bought a new stake in 10x Genomics in the 4th quarter valued at $3,206,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, February 13th. Stifel Nicolaus cut their price target on 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Barclays dropped their price objective on 10x Genomics from $15.00 to $12.00 and set an "overweight" rating for the company in a report on Thursday. Citigroup dropped their price target on 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Tuesday, March 4th. Finally, Leerink Partners downgraded shares of 10x Genomics from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $25.00 to $12.00 in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, 10x Genomics has an average rating of "Hold" and an average target price of $19.79.

10x Genomics Stock Performance

Shares of 10x Genomics stock traded up $0.21 during mid-day trading on Monday, hitting $8.22. 354,048 shares of the stock were exchanged, compared to its average volume of 2,162,530. The company has a market capitalization of $1.00 billion, a P/E ratio of -5.40 and a beta of 2.01. The company has a 50-day simple moving average of $10.44 and a 200 day simple moving average of $13.90. 10x Genomics, Inc. has a 12 month low of $6.78 and a 12 month high of $34.67.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current year.

Insider Transactions at 10x Genomics

In related news, Director Alan Mateo purchased 40,000 shares of the business's stock in a transaction that occurred on Friday, February 21st. The shares were acquired at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. The trade was a 184.41 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the firm's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now directly owns 335,324 shares of the company's stock, valued at approximately $3,712,036.68. This represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.